These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 37500124)

  • 1. Prognostic Value of TACE With Irinotecan-loaded Drug-eluting Beads (DEBIRI) in Patients With Liver Metastases from Unresectable Colorectal Cancer.
    Ishikawa T; Imai M; Sato R; Jimbo R; Kobayashi Y; Sato T; Iwanaga A; Sano T; Yokoyama J; Honma T
    Anticancer Res; 2023 Aug; 43(8):3647-3651. PubMed ID: 37500124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic factors for overall survival and safety of trans-arterial chemoembolization (TACE) with irinotecan-loaded drug-eluting beads (DEBIRI) in patients with colorectal liver metastases.
    Sljivic M; Sever M; Ocvirk J; Mesti T; Brecelj E; Popovic P
    Radiol Oncol; 2024 Jun; 58(2):214-220. PubMed ID: 38553252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transarterial chemoembolization using DEBIRI for treatment of hepatic metastases from colorectal cancer.
    Narayanan G; Barbery K; Suthar R; Guerrero G; Arora G
    Anticancer Res; 2013 May; 33(5):2077-83. PubMed ID: 23645758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Toxicity of Hepatic Intra-Arterial Drug-Eluting (Irinotecan) Bead (DEBIRI) Therapy in Irinotecan-Refractory Unresectable Colorectal Liver Metastases.
    Bhutiani N; Akinwande O; Martin RC
    World J Surg; 2016 May; 40(5):1178-90. PubMed ID: 26711640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transarterial chemoembolization with irinotecan beads in the treatment of colorectal liver metastases: systematic review.
    Richardson AJ; Laurence JM; Lam VW
    J Vasc Interv Radiol; 2013 Aug; 24(8):1209-17. PubMed ID: 23885916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small Particle DEBIRI TACE as Salvage Therapy in Patients with Liver Dominant Colorectal Cancer Metastasis: Retrospective Analysis of Safety and Outcomes.
    Voizard N; Ni T; Kiss A; Pugash R; Raphael MJ; Coburn N; David E
    Curr Oncol; 2022 Jan; 29(1):209-220. PubMed ID: 35049694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transarterial chemoembolisation (TACE) using irinotecan-loaded beads for the treatment of unresectable metastases to the liver in patients with colorectal cancer: an interim report.
    Martin RC; Robbins K; Tomalty D; O'Hara R; Bosnjakovic P; Padr R; Rocek M; Slauf F; Scupchenko A; Tatum C
    World J Surg Oncol; 2009 Nov; 7():80. PubMed ID: 19886993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complete pathological response of unresectable liver metastases from colorectal cancer after trans-arterial chemoembolization with drug-eluting beads loaded with irinotecan (DEBIRI) and concomitant systemic FOLFOX: A case report from the FFCD 1201 trial.
    Pernot S; Artru P; Mithieux F; Marsot J; Watkin E; Pellerin O; Lledo G; Chalabreysse P; Desramé J; Taieb J
    Clin Res Hepatol Gastroenterol; 2015 Dec; 39(6):e73-7. PubMed ID: 26141343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The power of genes: a case of unusually severe systemic toxicity after localized hepatic chemoembolization with irinotecan-eluted microspheres for metastatic colon cancer.
    Cruz JE; Saksena R; Jabbour SK; Nosher JL; Hermes-DeSantis E; Moss RA
    Ann Pharmacother; 2014 Dec; 48(12):1646-50. PubMed ID: 25202035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemoembolization with drug eluting beads preloaded with irinotecan (DEBIRI) vs doxorubicin (DEBDOX) as a second line treatment for liver metastases from cholangiocarcinoma: a preliminary study.
    Venturini M; Sallemi C; Agostini G; Marra P; Cereda S; Reni M; Aldrighetti L; De Cobelli F; Del Maschio A
    Br J Radiol; 2016 Nov; 89(1067):20160247. PubMed ID: 27558984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Irinotecan eluting beads-transarterial chemoembolization using Callispheres® microspheres is an effective and safe approach in treating unresectable colorectal cancer liver metastases.
    Zhao G; Liu S; Zhang Y; Zhao T; Wang R; Bian J; Wu J; Zhou J
    Ir J Med Sci; 2022 Jun; 191(3):1139-1145. PubMed ID: 34264426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug-eluting beads loaded with irinotecan to treat synchronous liver-only metastases of colorectal cancer non-responsive to bevacizumab-based chemotherapy.
    Hsu TF; Chang WC; Chang PY; Lin HH; Chen PK; Ko KH; Chiu SH
    Br J Radiol; 2023 Apr; 96(1145):20220767. PubMed ID: 36802795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Irinotecan drug-eluting beads in the treatment of chemo-naive unresectable colorectal liver metastasis with concomitant systemic fluorouracil and oxaliplatin: results of pharmacokinetics and phase I trial.
    Martin RC; Scoggins CR; Tomalty D; Schreeder M; Metzger T; Tatum C; Sharma V
    J Gastrointest Surg; 2012 Aug; 16(8):1531-8. PubMed ID: 22528576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transarterial Chemoembolisation of Colorectal Liver Metastases with Irinotecan-Loaded Beads: A Bi-institutional Analysis of 125 Treatments in 53 Patients.
    Ngo A; von Stempel C; Corbo B; Bandula S; Shiu KK; Raja J; Hague J; Evans J; Kibrya N
    Cardiovasc Intervent Radiol; 2019 Jul; 42(7):979-990. PubMed ID: 31044294
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does Bead Size Affect Patient Outcome in Irinotecan-Loaded Beads Chemoembolization Plus Systemic Chemotherapy Regimens for Liver-Dominant Colorectal Cancer? Results of an Observational Study.
    Boeken T; Moussa N; Pernot S; Abed A; Dean C; Taieb J; Sapoval M; Pellerin O
    Cardiovasc Intervent Radiol; 2020 Jun; 43(6):866-874. PubMed ID: 32103303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized controlled trial of irinotecan drug-eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver-limited metastasis.
    Martin RC; Scoggins CR; Schreeder M; Rilling WS; Laing CJ; Tatum CM; Kelly LR; Garcia-Monaco RD; Sharma VR; Crocenzi TS; Strasberg SM
    Cancer; 2015 Oct; 121(20):3649-58. PubMed ID: 26149602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early Experience with 70-150 μm Irinotecan Drug-eluting Beads (M1-DEBIRI) for the Treatment of Unresectable Hepatic Colorectal Metastases.
    Akinwande O; Scoggins C; Martin RC
    Anticancer Res; 2016 Jul; 36(7):3413-8. PubMed ID: 27354601
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiological assessment of response to neoadjuvant transcatheter hepatic therapy with irinotecan-eluting beads (DEBIRI(®)) for colorectal liver metastases does not predict tumour destruction or long-term outcome.
    Jones RP; Stättner S; Dunne DF; O'Grady E; Smethurst A; Terlizzo M; Malik HZ; Fenwick SW; Poston GJ
    Eur J Surg Oncol; 2013 Oct; 39(10):1122-8. PubMed ID: 23928482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review of the Clinical Evidence for the Use of DEBIRI in the Treatment of Colorectal Metastatic Disease.
    Young S; D'Souza D; Flanagan S; Golzarian J
    Cardiovasc Intervent Radiol; 2017 Apr; 40(4):496-501. PubMed ID: 28004168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PARAGON II - A single arm multicentre phase II study of neoadjuvant therapy using irinotecan bead in patients with resectable liver metastases from colorectal cancer.
    Jones RP; Malik HZ; Fenwick SW; Terlizzo M; O'Grady E; Stremitzer S; Gruenberger T; Rees M; Plant G; Figueras J; Albiol M; Adam R; Awad S; Poston GJ
    Eur J Surg Oncol; 2016 Dec; 42(12):1866-1872. PubMed ID: 27561844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.